Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted; the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:

Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)
‘006-035-00-8	pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate	245-430-1	23103-98-2	Carc. 2 Acute Tox. 3 Acute Tox. 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H331 H301 H317 H400 H410	GHS08 GHS06 GHS09 Dgr	H351 H331 H301 H317 H410		M = 10 M = 100’
‘029-002-00-X	dicopper oxide; copper (I) oxide	215-270-7	1317-39-1	Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H332 H302 H318 H410		M = 100’
‘602-020-00-0	1,2-dichloropropane; propylene dichloride	201-152-2	78-87-5	Flam. Liq. 2 Carc. 1B Acute Tox. 4* Acute Tox. 4*	H225 H350 H332 H302	GHS02 GHS08 GHS07 Dgr	H225 H350 H332 H302’
‘602-033-00-1	chlorobenzene	203-628-5	108-90-7	Flam. Liq. 3 Acute Tox. 4 Skin Irrit. 2 Aquatic Chronic 2	H226 H332 H315 H411	GHS02 GHS07 GHS09 Wng	H226 H332 H315 H411’
‘603-055-00-4	propylene oxide; 1,2-epoxypropane; methyloxirane	200-879-2	75-56-9	Flam. Liq. 1 Carc. 1B Muta. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Irrit. 2	H224 H350 H340 H331 H311 H302 H335 H319	GHS02 GHS08 GHS06 Dgr	H224 H350 H340 H331 H311 H302 H335 H319’
‘604-030-00-0	bisphenol A; 4,4′-isopropylidenediphenol	201-245-8	80-05-7	Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1	H360F H335 H318 H317	GHS08 GHS05 GHS07 Dgr	H360F H335 H318 H317’
‘604-092-00-9	phenol, dodecyl-, branched; [1] phenol, 2-dodecyl-, branched; [2] phenol, 3-dodecyl-, branched; [3] phenol, 4-dodecyl-, branched; [4] phenol, (tetrapropenyl) derivatives [5]	310-154-3 [1] [2] [3] [4] [5]	121158-58-5 [1] [2] [3] 210555-94-5 [4] 74499-35-7 [5]	Repr. 1B Skin Corr. 1C Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H360F H314 H318 H400 H410	GHS08 GHS05 GHS09 Dgr	H360F H314 H410		M = 10 M = 10’
‘605-013-00-0	chloralose (INN); (R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral	240-016-7	15879-93-3	Acute Tox. 4* Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1	H332 H301 H336 H400 H410	GHS06 GHS09 Dgr	H332 H301 H336 H410		M = 10 M = 10	C’
‘605-022-00-X	glutaral; glutaraldehyde; 1,5-pentanedial	203-856-5	111-30-8	Acute Tox. 2 Acute Tox. 3 STOT SE 3 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2	H330 H301 H335 H314 H334 H317 H400 H411	GHS06 GHS05 GHS08 GHS09 Dgr	H330 H301 H335 H314 H334 H317 H410	EUH071	STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1’
‘606-014-00-9	chlorophacinone (ISO); 2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione	223-003-0	3691-35-8	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,1 % STOT RE 2; H373 (blood): 0,01 % ≤ C < 0,1 % M = 1 M = 1’
‘606-021-00-7	N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone	212-828-1	872-50-4	Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Irrit. 2	H360D*** H335 H315 H319	GHS08 GHS07 Dgr	H360D*** H335 H315 H319		STOT SE 3; H335: C ≥ 10 %’
‘607-056-00-0	warfarin (ISO); 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1] (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2] (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]	201-377-6 [1] 226-907-3 [2] 226-908-9 [3]	81-81-2 [1] 5543-57-7 [2] 5543-58-8 [3]	Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE 1 Aquatic Chronic 2	H360D H330 H310 H300 H372 (blood) H411	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H411		Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,5 % STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’
‘607-059-00-7	coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin	227-424-0	5836-29-3	Repr. 1B Acute Tox. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Chronic 1	H360D H330 H311 H300 H372 (blood) H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H311 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 1,0 % STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 % M = 10’
‘607-157-00-X	difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin	259-978-4	56073-07-5	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’
‘607-172-00-1	brodifacoum (ISO); 4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin	259-980-5	56073-10-0	Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’
‘607-375-00-5	flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin	421-960-0	90035-08-8	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,05 % STOT RE 2; H373 (blood): 0,005 % ≤ C < 0,05 % M = 10 M = 10’
‘607-623-00-2	diisobutyl phthalate	201-553-2	84-69-5	Repr. 1B	H360Df	GHS08 Dgr	H360Df’
‘613-166-00-X	flumioxazin (ISO); 2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	—	103361-09-7	Repr. 1B Aquatic Acute 1 Aquatic Chronic 1	H360D H400 H410	GHS08 GHS09 Dgr	H360D H410		M = 1 000 M = 1 000’
‘613-121-00-4	chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide	265-268-5	64902-72-3	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 000 M = 100’
‘616-011-00-4	N,N-dimethylacetamide	204-826-4	127-19-5	Repr. 1B Acute Tox. 4* Acute Tox. 4*	H360D*** H332 H312	GHS08 GHS07 Dgr	H360D*** H332 H312’
‘616-037-00-6	acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide	251-899-3	34256-82-1	Carc. 2 Repr. 2 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H361f H332 H335 H373 (kidney) H315 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H361f H332 H335 H373 (kidney) H315 H317 H410		M = 1 000 M = 100’
‘616-207-00-X	polyhexamethylene biguanide hydrochloride; PHMB	—	32289-58-0 27083-27-8	Carc. 2 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H410		M = 10 M = 10’

the following entries are inserted in accordance with the order of the index numbers:

Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)
‘005-020-00-3	disodium octaborate anhydrous; [1] disodium octaborate tetrahydrate [2]	234-541-0 [1] 234-541-0 [2]	12008-41-2 [1] 12280-03-4 [2]	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘014-046-00-4	e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]	—	—	Carc. 1B	H350i	GHS08 Dgr	H350i			A’
‘014-047-00-X	glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]	—	—	Carc. 2	H351 (inhalation)	GHS08 Wng	H351 (inhalation)			A’
‘029-015-00-0	copper thiocyanate	214-183-1	1111-67-7	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410	EUH032	M = 10’
‘029-016-00-6	copper(II) oxide	215-269-1	1317-38-0	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 100’
‘029-017-00-1	dicopper chloride trihydroxide	215-572-9	1332-65-6	Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H332 H301 H400 H410	GHS06 GHS09 Dgr	H332 H301 H410		M = 10’
‘029-018-00-7	tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2]	215-582-3 [1] 215-582-3 [2]	1333-22-8 [1] 12527-76-3 [2]	Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H302 H400 H410	GHS07 GHS09 Wng	H302 H410		M = 10’
‘029-019-01-X	copper flakes (coated with aliphatic acid)	—	—	Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H331 H302 H319 H400 H410	GHS06 GHS09 Dgr	H331 H302 H319 H410		M = 10’
‘029-020-00-8	copper(II) carbonate--copper(II) hydroxide (1:1)	235-113-6	12069-69-1	Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H319 H400 H410	GHS07 GHS09 Wng	H332 H302 H319 H410		M = 10’
‘029-021-00-3	copper dihydroxide; copper(II) hydroxide	243-815-9	20427-59-2	Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H318 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H302 H318 H410		M = 10’
‘029-022-00-9	bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide	—	8011-63-0	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H332 H318 H410		M = 10’
‘029-023-00-4	copper sulphate pentahydrate	231-847-6	7758-99-8	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H302 H318 H410		M = 10’
‘082-013-00-1	lead powder; [particle diameter < 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact.	H360FD H362	GHS08 Dgr	H360FD H362		Repr. 1A; H360D: C ≥ 0,03 %’
‘082-014-00-7	lead massive: [particle diameter ≥ 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact.	H360FD H362	GHS08 Dgr	H360FD H362’
‘605-040-00-8	hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1] 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2] 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]	- [1] 250-863-4 [2] 257-187-9 [3]	130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3]	Skin Sens. 1A	H317	GHS07 Wng	H317’
‘607-716-00-8	bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one	249-205-9	28772-56-7	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood): 0,0005 % ≤ C < 0,005 % M = 1 M = 1’
‘607-717-00-3	difethialone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one	—	104653-34-1	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410	EUH070	Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 100 M = 100’
‘607-718-00-9	perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts	206-801-3 [1] [2] [3]	375-95-1 [1] 21049-39-8 [2] 4149-60-4 [3]	Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1	H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318	GSH08 GSH07 GHS05 Dgr	H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318’
‘607-719-00-4	dicyclohexyl phthalate	201-545-9	84-61-7	Repr. 1B Skin Sens. 1	H360D H317	GHS08 GHS07 Dgr	H360D H317’
‘608-067-00-3	3,7-dimethylocta-2,6-dienenitrile	225-918-0	5146-66-7	Muta. 1B	H340	GHS08 Dgr	H340’
‘612-288-00-0	bupirimate (ISO); 5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate	255-391-2	41483-43-6	Carc. 2 Skin Sens. 1B Aquatic Chronic 1	H351 H317 H410	GHS08 GHS07 GHS09 Wng	H351 H317 H410		M = 1’
‘612-289-00-6	triflumizole (ISO); (1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine	—	68694-11-1	Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H302 H373 (liver) H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H360D H302 H373 (liver) H317 H410		M = 1 M = 1’
‘616-218-00-X	benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide	—	1072957-71-1	Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H331 H301 H400 H410	GHS06 GHS09 Dgr	H331 H301 H410		M = 100 M = 100’
‘616-219-00-5	fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide	—	658066-35-4	Aquatic Chronic 2	H411	GHS09	H411’
‘616-220-00-0	pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea	266-096-3	66063-05-6	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1’
‘617-023-00-2	tert-butyl hydroperoxide	200-915-7	75-91-2	Muta. 2	H341	GHS08 Wng	H341’